Kiran Reddy Kanubaddi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kiran Reddy Kanubaddi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ai-Zheng Chen
Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, China
1 shared publication - Chen-Guang Liu
The affiliated 903 Hospital of Zhejiang Sci‐Tech University, Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, Zhejiang Provincial Key Laboratory of Drug Discovery and Development for Metabolic Diseases College of Life Sciences and Medicine Hangzhou Zhejiang Province China
1 shared publication Chia-Hung Lee
Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan,
1 shared publicationChia‐Hung Lee
Department of Life Science and Institute of Biotechnology National Dong Hwa University Hualien 97401 Taiwan
1 shared publication- Ching-Feng Weng
Department of Physiology, School of Basic Medical Sciences, Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Xiamen 361023, China
1 shared publication - Helder Almeida Santos
Department of Biomaterials and Biomedical Technology The Personalized Medicine Research Institute (PRECISION) University Medical Center Groningen University of Groningen Groningen The Netherlands
1 shared publication
Latest Publications
- 8 August 2019
- Published by Wiley in Advanced Functional Materials
- Vol. 29 (43) , 1902652
Metal Species–Encapsulated Mesoporous Silica Nanoparticles: Current Advancements and Latest Breakthroughs
Despite their advantageous morphological attributes and attractive physicochemical properties, mesoporous silica nanoparticles (MSNs) are merely supported as carriers or vectors for a reason. Incorporating various metal species in the confined nanospaces of MSNs (M‐MSNs) significantly enriches their mesoporous architecture and diverse functionalities, bringing exciting potentials to this burgeoning field of research. These incorporated guest species offer enormous benefits to the MSN hosts concerning the reduction of their eventual size and the enhancement of their performance and stability, among other benefits. Substantially, the guest species act through contributing to reduced aggregation, augmented durability, ease of long‐term storage, and reduced toxicity, attributes that are of particular interest in diverse fields of biomedicine. In this review, the first aim is to discuss the current advancements and latest breakthroughs in the fabrication of M‐MSNs, emphasizing the pros and cons, the confinement of various metal species in the nanospaces of MSNs, and various factors influencing the encapsulation of metal species in MSNs. Further, an emphasis on potential applications of M‐MSNs in various fields, including in adsorption, catalysis, photoluminescence, and biomedicine, among others, along with a set of examples is provided. Finally, the advances in M‐MSNs with perspectives are summarized.
- 8 August 2019
- Published by Wiley in Advanced Functional Materials
- Vol. 29 (43) , 1902652
Metal Species–Encapsulated Mesoporous Silica Nanoparticles: Current Advancements and Latest Breakthroughs
Despite their advantageous morphological attributes and attractive physicochemical properties, mesoporous silica nanoparticles (MSNs) are merely supported as carriers or vectors for a reason. Incorporating various metal species in the confined nanospaces of MSNs (M‐MSNs) significantly enriches their mesoporous architecture and diverse functionalities, bringing exciting potentials to this burgeoning field of research. These incorporated guest species offer enormous benefits to the MSN hosts concerning the reduction of their eventual size and the enhancement of their performance and stability, among other benefits. Substantially, the guest species act through contributing to reduced aggregation, augmented durability, ease of long‐term storage, and reduced toxicity, attributes that are of particular interest in diverse fields of biomedicine. In this review, the first aim is to discuss the current advancements and latest breakthroughs in the fabrication of M‐MSNs, emphasizing the pros and cons, the confinement of various metal species in the nanospaces of MSNs, and various factors influencing the encapsulation of metal species in MSNs. Further, an emphasis on potential applications of M‐MSNs in various fields, including in adsorption, catalysis, photoluminescence, and biomedicine, among others, along with a set of examples is provided. Finally, the advances in M‐MSNs with perspectives are summarized.
- Open Access
- 1 December 2018
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 13, 8473-8485
Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation
Alzheimer’s disease (AD), an age-related neurodegenerative disease, the most common causes of dementia is a multifactorial pathology categorized by a complex etiology. Numerous nutraceuticals have been clinically evaluated, but some of the trials failed. However, natural compounds have some limitations due to their poor bioavailability, ineffective capability to cross the blood–brain barrier, or less therapeutic effects on AD. To overcome these disadvantages, nanoparticle-conjugated natural products could promote the bioavailability and enhance the therapeutic efficacy of AD when compared with a naked drug. This application generates and implements new prospect for drug discovery in neurodegenerative diseases. In this article, we confer AD pathology, review natural products in clinical trials, and ascertain the importance of nanomedicine coupled with natural compounds for AD.
- 1 December 2018
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 13, 8473-8485
Open AccessNanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation
Alzheimer’s disease (AD), an age-related neurodegenerative disease, the most common causes of dementia is a multifactorial pathology categorized by a complex etiology. Numerous nutraceuticals have been clinically evaluated, but some of the trials failed. However, natural compounds have some limitations due to their poor bioavailability, ineffective capability to cross the blood–brain barrier, or less therapeutic effects on AD. To overcome these disadvantages, nanoparticle-conjugated natural products could promote the bioavailability and enhance the therapeutic efficacy of AD when compared with a naked drug. This application generates and implements new prospect for drug discovery in neurodegenerative diseases. In this article, we confer AD pathology, review natural products in clinical trials, and ascertain the importance of nanomedicine coupled with natural compounds for AD.